Cargando…
Heterogeneity of p53-pathway Protein Expression in Chemosensitive Chronic Lymphocytic Leukemia: A Pilot Study
The presence of p53-pathway dysfunction in chronic lymphocytic leukemia (CLL) can be used to identify patients with chemotherapy-refractory disease. Therapeutic responses are known to vary between patients with chemosensitive CLL and may relate to differences in p53-pathway activity. We hypothesized...
Autores principales: | Groves, Michael J, MacCallum, Stephanie F, Boylan, Michael T, Haydock, Sally, Cunningham, Joan, Gelly, Keith, Gowans, Duncan, Kerr, Ron, Coates, Philip J, Tauro, Sudhir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434363/ https://www.ncbi.nlm.nih.gov/pubmed/22962562 http://dx.doi.org/10.7150/jca.4813 |
Ejemplares similares
-
Dysregulation of autophagy in chronic lymphocytic leukemia with the small-molecule Sirtuin inhibitor Tenovin-6
por: MacCallum, Stephanie F., et al.
Publicado: (2013) -
p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia
por: Groves, M J, et al.
Publicado: (2013) -
Chemosensitivity and p53; new tricks by an old dog
por: Lønning, Per E, et al.
Publicado: (2012) -
Gastric cancer--the recognition of a chemosensitive tumour.
por: Cunningham, D.
Publicado: (1988) -
Association of p53 and mitochondrial gene with chemosensitization by metformin in ovarian cancer
por: Wei, De-Hua, et al.
Publicado: (2017)